Ad image

AZD1222 vaccine meets primary efficacy endpoint in preventing COVID-19

David Adenekan
David Adenekan
Vaccine

AZD1222 vaccine has been declared to have met primary efficacy endpoint in preventing COVID-19.

Two different dosing regimens were reported to have demonstrated efficacy with one showing a better profile; No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222.

The announcement was made on Tuesday in statement issued by APO Group on behalf of AstraZeneca.

The statement reads: “Today marks an important step in turning the corner on the pandemic and getting things back to normal. Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil, which showed the vaccine was highly effective in preventing COVID-19, we are confident that our united response, across the scientific community, industry, organisations, and governments, will make significant inroads in curbing the COVID-19 pandemic that has continued to claim thousands of lives every day in Africa and across the globe.

“We will continue to work hard to honour our commitment to make the vaccine available in a fair and equitable manner as rapidly as possible, following robust regulatory approval and meeting stringent efficacy and safety standards. It is a great day for innovation and for inclusion, an exciting moment for human health.”

AstraZeneca (www.AstraZeneca.com) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *